Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab - Concepedia

Concepedia

Publication | Open Access

Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab

DOI Full Paper Access

150

Citations

17

References

2017

Year

David Laharie, Arnaud Bourreille, Julien Branche, Matthieu Allez, Yoram Bouhnik, Jérôme Filippi, Frank Zerbib, Guillaume Savoye, Lucine Vuitton, J. Moreau,

Abstract

EudraCT: 2006-005299-42; ClinicalTrials.gouv number: NCT00542152; post-results.

References

	Year	Citations
The Statistical Analysis of Failure Time Data. Murray Aitkin, John D. Kalbfleisch, Ross L. Prentice Biometrics ReliabilityReliability EngineeringEngineeringFailure AnalysisFailure Time Data	1981	10K
The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications Jack Satsangi Gut InflammationChronic Inflammatory DiseasesRheumatologyEpidemiologyMontreal Classification	2006	3.1K
Cortisone in Ulcerative Colitis S. C. Truelove, L. J. Witts BMJ	1955	2.8K
Cyclosporine in Severe Ulcerative Colitis Refractory to Steroid Therapy Simon Lichtiger, D. H. Present, Asher Kornbluth, New England Journal of Medicine	1994	1.7K
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management James O. Lindsay, Andreas Sturm, Alastair Windsor, Journal of Crohn s and Colitis GastroenterologyDiagnosisClinical SpecialtiesSevere UcSurgery	2012	1.5K
Infliximab as Rescue Therapy in Severe to Moderately Severe Ulcerative Colitis: A Randomized, Placebo-Controlled Study Gunnar Järnerot, Erik Hertervig, Ingalill Friis–Liby, Gastroenterology InflammationAnti-inflammatoryGastroenterologyPlacebo-controlled StudyUlcerative Colitis	2005	1.1K
The course and prognosis of ulcerative colitis: Part I Short-term prognosis F Edwards, S. C. Truelove Gut Unique StudyChurchill HospitalGastroenterologyPathologyClinical Gastroenterology	1963	860
Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial David Laharie, Arnaud Bourreille, Julien Branche, The Lancet InflammationAnti-inflammatoryGastroenterologyIntravenous SteroidsUlcerative Colitis	2012	633
Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study Mirthe E. van der Valk, Marie‐Josée J. Mangen, Max Leenders, Gut	2012	491
Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis1 1Gert Van Assche, Severine Vermeire, Geert D’Haens, and Paul Rutgeerts have been instrumental in the design of the study, trial management, data analysis, and writing the paper. Maja Noman had a major contribution in the clinical ambulatory follow-up of the patients in the trial. Martin Hiele followed cyclosporine levels and adjusted drug doses of patients in the trial and provided statistical advice. Katrien Asnong was the study coordinator and had a major share in data analysis. Joris Arts analyzed safety data and followed patients clinically during the trial. Andre D’Hoore and Freddy Penninckx performed the surgical interventions in patients failing the trial and substantially contributed in evaluating patients for colectomy. Gert Van Assche, Geert D’Haens, Maja Noman, Gastroenterology	2003	445

Page 1